Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 5, 2013, Pages 482-493

  Bosch, Maria Neus ^a,b   Gimeno Bayón, Javier ^a,b   Rodríguez, Manuel J ^b   Pugliese, Marco ^b   Mahy, Nicole ^b  

^a Medivet Pharma SL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

A ; Alzheimer's disease; Amyloid vaccine; Canine cognitive dysfunction syndrome; Dog; Immunotherapy

Indexed keywords

ALKALINE PHOSPHATASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN G; PLACEBO;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOG; FEMALE; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNODETECTION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RABBIT; RETICULOCYTE COUNT;

AGE FACTORS; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOGS; ELIMINATIVE BEHAVIOR, ANIMAL; EXPRESSED EMOTION; FEMALE; HEMATOLOGIC TESTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MALE; PEPTIDE FRAGMENTS; RABBITS; WALKING;

EID: 84888240086     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990129     Document Type: Article

References (61)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer'sdisease. Lancet 377: 1019-1031 (2011).
2. Hardy J, Selkoe DJ. The Amyloid Hypothesis of Alzheimer's Dis-ease: Progress and Problems on the Road to Therapeutics. Science 297: 353-356 (2002).
3. Sánchez L, Madurga S, Pukala T, Vilaseca M, López-Iglesias C, Robinson CV, et al. Ap40 and Ap42 amyloid fibrils exhibit distinct molecular recycling properties. J Am Chem Soc 133: 6505-6508 (2011).
4. Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Ta-tsuno G, et al. High-Level Neuronal Expression of Ap1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. J Neurosci 20: 4050-4058 (2000).
5. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oli-gomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352-358 (2009).
6. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19: R12-20 (2010).
7. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982 (2000).
8. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985 (2000).
9. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, et al. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Disease 23: 351-361 (2006).
10. Boche D, Denham N, Holmes C, Nicoll JAR. Neuropathology after active Ap42 immunotherapy: implications for Alzheimer's disease pathogenesis. ActaNeuropathol 120: 369-384 (2010).
11. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15: 505-514 (2003).
12. Axelsen TV, Holm A, Christiansen G, Birkelund S. Identification of the shortest Abeta-peptide generating highly specific antibodies against the C-terminal end of amyloid-[beta]42. Vaccine 29: 3260-3269 (2011).
13. Bosch MN, Pugliese M, Gimeno-Bayón J, Rodríguez MJ, Mahy N. Dogs with Cognitive Dysfunction Syndrome: A Natural Model of Alzheimer's Disease. Curr Alzheimer Res 9(3): 298-314 (2012).
14. Head E, Pop V, Sarsoza F, Kayed R, Beckett TL, Studzinski CM, et al. Amyloid-p Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines. J. Alzheimer's Dis 20: 637-646 (2010).
15. Ruehl WW, Bruyette DS, DePaoli A, Cotman CW, Head E, Mil-gram NW, et al. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and re-sponse to 1-deprenyl therapy. Prog Brain Res106: 217-225 (1995).
16. Russell MJ, Bobik M, White RG, Hou Y, Benjamin SA, Geddes JW. Age-specific onset of beta-amyloid in beagle brains. Neurobiol Aging 17: 269-273 (1996).
17. Pugliese M, Carrasco JL, Geloso MC, Mascort J, Michetti F, Mahy N. Y. Aminobutyricacidergic interneuron vulnerability to aging in canine prefrontal cortex. J Neurosci Res 77: 913-920 (2004).
18. Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 88: 475-486 (2010).
19. Cotman CW, Head E. The Canine (Dog) Model of Human Aging and Disease: Dietary, Environmental and Immunotherapy Approaches. J Alzheimer's Dis 15: 685-707 (2008).
20. Rofina JE, van Ederen AM, Toussaint MJM, Secreve M, van der Spek A, van der Meer I, et al. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res 1069: 216-226 (2006).
21. Pugliese M, Carrasco JL, Andrade C, Mas E, Mascort J, Mahy N. Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia. Prog Neuro-Psychopharmacol Biol Psychiatry 29: 603-610 (2005).
22. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, et al. A Two-Year Study with Fibrillar {beta}-Amyloid Abeta Immunization in Aged Canines: Effects on Cognitive Function and Brain Abeta. J Neurosci 28: 3555-3566 (2008).
23. Vasilevko V, Pop V, Kim HJ, Saing T, Glabe CC, Milton S, et al. Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis 39: 301-310 (2010).
24. Pugliese M, Geloso MC, Carrasco JL, Mascort J, Michetti F, Mahy N. Canine cognitive deficit correlates with diffuse plaque maturation and S100p (-) astrocytosis but not with insulin cerebrospinal fluid level. Acta Neuropathol 111: 519-528 (2006).
25. Araujo JA, Greig NH, Ingram DK, Sandin J, de Rivera C, Milgram NW. Cholinesterase Inhibitors Improve Both Memory and Complex Learning in Aged Beagle Dogs. J Alzheimers Dis 26(1): 143-55 (2011).
26. Milgram NW. Cognitive experience and its effect on age-dependent cognitive decline in beagle dogs. Neurochem Res 28: 1677-1682 (2003).
27. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1: 213-216 (1991).
28. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J Clin Lab Invest 37: 385-390 (1977).
29. Pugliese M, Mascort J, Mahy N, Ferrer I. Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neuropathol 112: 175-183 (2006).
30. Skoumalova A, Rofina J, Schwippelova Z, Gruys E, Wilhelm J. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol 38: 711-719 (2003).
31. Vajdovich P, Gaál T, Szilágyi A, Harnos A. Changes in some red blood cell and clinical laboratory parameters in young and old Beagle dogs. Vet Res Commun 21: 463-470 (1997).
32. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 13: 914-917 (2005).
33. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MMB. PlasmaAbeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5: 655-660 (2006).
34. González-Martínez A, Rosado B, Pesini P, Suárez M-L, Santama-rina G, García-Belenguer S, et al. Plasma p-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. Exp Gerontol 46(7): 590-6 (2011).
35. Morita T, Mizutani Y, Sawada M, Shimada A. Immunohistochemi-cal and ultrastructural findings related to the blood--brain barrier in the blood vessels of the cerebral white matter in aged dogs. J Comp Pathol 133: 14-22 (2005).
36. Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg M, et al. Blood-brain-barrier alterations in ageing and dementia. J Neurological Sciences 283: 99-106 (2009).
37. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Sven-nerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 81: 323-326 (1990).
38. Tipold A, Pfister H, Zurbriggen A, Vandevelde M. Intrathecal synthesis of major immunoglobulin classes in inflammatory diseases of the canine CNS. Vet Immunol Immunopathol 42: 149-159 (1994).
39. Hampel H, Kötter HU, Padberg F, Körschenhausen DA, Möller HJ. Oligoclonal Bands and Blood-Cerebrospinal-Fluid Barrier Dysfunction in a Subset of Patients with Alzheimer Disease: Comparison with Vascular Dementia, Major Depression, and Multiple Sclerosis. Alzheimer Dis & Associated Disorders 13: (1999).
40. Webb AA, Muir GD. The blood-brain barrier and its role in inflammation. J Vet Intern Med 14: 399-411 (2000).
41. Kleine TO, Hackler R, Zöfel P. Age-related alterations of the blood-brain-barrierpermeability to protein molecules of different size. Z Gerontol 26: 256-259 (1993).
42. Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology 76: 247-252 (2011).
43. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60: 652-656 (2003).
44. Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519 (2006).
45. Rami L, Fortea J, Bosch B, Solé-Padullés C, Lladó A, Iranzo A, et al. Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. J Alzheimer's Dis 23: 319-326 (2011).
46. Tekirian TL, Cole GM, Russell MJ, Yang F, Wekstein DR, Patel E, et al. Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. Neurobiol Aging 17: 249-257 (1996).
47. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3: 16-32 (1996).
48. Miyawaki K, Nakayama H, Matsuno S, Tamaoka A, Doi K. Three-dimensional and fractal analyses of assemblies of amyloid beta pro-tein subtypes Abeta40 and Abeta42(43) in canine senile plaques. ActaNeuropathol 103: 228-236 (2002).
49. Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med 14: 451-464 (2008).
50. Burns EA, Lum LG, L'Hommedieu G, Goodwin JS. Specific humoral immunity in the elderly: in vivo and in vitro response to vaccination. J Gerontol 48: B231-236 (1993).
51. Schnabel J. Vaccines: Chasing the dream. Nature 475: S18-S19 (2011).
52. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119 (2010).
53. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid p protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23: 2223-2226 (2002).
54. Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, et al. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport 18: 293-296 (2007).
55. Miller DL, Potempska A, Mehta PD. Humoral immune responses to peptides derived from the p-amyloid peptide C-terminal sequence. Amyloid 14: 39-50 (2007).
56. von Bubnoff A. Vaccines to antibodies: grow up! IAVI Rep 14: 4-9 (2010).
57. Zhang Y, Lee DHS. Sink Hypothesis and Therapeutic Strategies for Attenuating Ap Levels. The Neuroscientist 17: 163-173 (2011).
58. Deane R, Bell R, Sagare A, Zlokovic B. Clearance of amyloid-p peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS NeurolDisord Drug Targets 8: 16-30 (2009).
59. Bachmeier CJ, Beaulieu-Abdelahad D, Mullan MJ, Paris D. Epi-tope-dependent effects of beta-amyloid antibodies on beta-amyloid clearance in an in vitro model of the blood-brain barrier. Microcirculation 18(5): 373-9 (2011).
60. Axelsen TV, Holm A, Birkelund S, Christiansen G, Ploug M, Holm IE. Specific recognition of the C-terminal end of Ap42 by a high affinity monoclonal antibody. Mol Immunol 46: 2267-2273 (2009).
61. Hatayama K, Nishihara Y, Kimura S, Goto K, Nakamura D, Wakita A, et al. Serum alkaline phosphatase isoenzymes in laboratory beagle dogs detected by polyacrylamide-gel disk electrophoresis. J Toxicol Sci 36: 653-660 (2011).